Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients.

Tytuł:
Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients.
Autorzy:
Voog E; Clinique Victor Hugo, Le Mans, France.
Campillo-Gimenez B; Centre Eugène Marquis, Rennes, France.
Elkouri C; Hôpital Privé du Confluent, Nantes, France.
Priou F; Centre Hospitalier de La Roche/Yon, La Roche/Yon, France.
Rolland F; Institut de Cancérologie de l'Ouest, Angers, Nantes, France.
Laguerre B; Centre Eugène Marquis, Rennes, France.
Elhannani C; Polyclinique du Parc, Cholet, France.
Merrer J; Clinique Pasteur, Brest, France.
Pfister C; Centre Hospitalier Universitaire, Rouen, France.
Sevin E; Centre François Baclesse, Caen, France.
L'Haridon T; Centre Hospitalier de La Roche/Yon, La Roche/Yon, France.
Hasbini A; Clinique Pasteur, Brest, France.
Moise L; Centre François Baclesse, Caen, France.
Le Rol A; Centre Hospitalier Intercommunal de Cornouaille, Quimper, France.
Malhaire JP; Centre Hospitalier Universitaire Brest Morvan, Brest, France.
Delva R; Institut de Cancérologie de l'Ouest, Angers, Nantes, France.
Vauléon E; Centre Eugène Marquis, Rennes, France.
Cojocarasu O; Centre Hospitalier Le Mans, Le Mans, France.
Deguiral P; Clinique Mutualiste de l'Estuaire Saint-Nazaire, Saint-Nazaire, France.
Cumin I; Centre Hospitalier Bretagne Sud Lorient, Lorient, France.
Cheneau C; Centre Hospitalier Universitaire Brest Morvan, Brest, France.; Centre Hospitalier Bretagne Sud Lorient, Lorient, France.
Schlürmann F; Centre Hospitalier Intercommunal de Cornouaille, Quimper, France.; Centre Hospitalier Universitaire Brest Morvan, Brest, France.
Delecroix V; Clinique Mutualiste de l'Estuaire Saint-Nazaire, Saint-Nazaire, France.
Boughalem E; Institut de Cancérologie de l'Ouest, Angers, Nantes, France.
Mollon D; Centre Hospitalier Intercommunal de Cornouaille, Quimper, France.
Ligeza-Poisson C; Clinique Mutualiste de l'Estuaire Saint-Nazaire, Saint-Nazaire, France.
Abadie-Lacourtoisie S; Institut de Cancérologie de l'Ouest, Angers, Nantes, France.
Monpetit E; Hôpital Privé Océane, Vannes, France.
Chatellier T; Clinique Mutualiste de l'Estuaire Saint-Nazaire, Saint-Nazaire, France.
Desclos H; Centre Hospitalier Saint-Malo, Saint-Malo, France.
Coquan E; Centre François Baclesse, Caen, France.
Joly F; Centre François Baclesse, Caen, France.
Tessereau JY; Institut de Cancérologie de l'Ouest, Angers, Nantes, France.; Observatoire dédié au Cancer des Pays de la Loire, Angers, France.
Dupuy S; Institut de Cancérologie de l'Ouest, Angers, Nantes, France.
Déniel Lagadec D; Centre Hospitalier Universitaire Brest Morvan, Brest, France.; Observatoire dédié au Cancer des Pays de la Loire, Angers, France.
Marhuenda F; Institut de Cancérologie de l'Ouest, Angers, Nantes, France.; Observatoire dédié au Cancer des Pays de la Loire, Angers, France.
Grudé F; Institut de Cancérologie de l'Ouest, Angers, Nantes, France.; Observatoire dédié au Cancer des Pays de la Loire, Angers, France.
Źródło:
International journal of cancer [Int J Cancer] 2020 Mar 15; Vol. 146 (6), pp. 1643-1651. Date of Electronic Publication: 2019 Aug 01.
Typ publikacji:
Journal Article; Observational Study
Język:
English
Imprint Name(s):
Publication: 1995- : New York, NY : Wiley-Liss
Original Publication: 1966-1984 : Genève : International Union Against Cancer
MeSH Terms:
Angiogenesis Inhibitors/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Kidney Neoplasms/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Bevacizumab/therapeutic use ; Carcinoma, Renal Cell/mortality ; Everolimus/therapeutic use ; Female ; France/epidemiology ; Humans ; Kidney Neoplasms/mortality ; Male ; Middle Aged ; Molecular Targeted Therapy/adverse effects ; Molecular Targeted Therapy/methods ; Patient Selection ; Prognosis ; Prospective Studies ; Risk Factors ; Survival Analysis ; Time Factors
References:
Surveillance, Epidemiology, and End Results Program (SEER). SEER stat fact sheets: kidney and renal pelvis cancer. Bethesda, MD: National Cancer Institute, 2016. http://seer.cancer.gov/statfacts/html/kidrp.html.
Rabinovitch RA, Zelefsky MJ, Gaynor JJ, et al. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 1994;12:206-12.
Sandock DS, Seftel AD, Resnick MI. A new protocol for the follow-up of renal cell carcinoma based on pathological stage. J Urol 1995;154:28-31.
Dabestani S, Thorstenson A, Lindblad P, et al. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol 2016;34:1081-6.
Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40.
Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-9.
Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312-8.
Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 2008;372:449-56.
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-13.
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Kidney Cancer. Version 2015. http://www.nccn.org/professionals/physicians_gls_guidelines.asp.
Escudier B, Eisen T, Porta C, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;65-71.
Escudier B, Kataja V, ESMO Guidelines Working Group. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;137-9.
Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378:1277-90.
Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:1103-15.
Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:1116-27.
Motzer RJ, Hutson TE, McCann L, et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014;370:1769-70.
Marschner N, Staehlner M, Müller L, et al. Survival of patients with advanced or metastatic renal cell carcinoma in routine practice differs from that in clinical trials-analyses from the German clinical RCC registry. Clin Genitourin Cancer 2017;15:e209-15.
Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol 2014;32:1412-8.
Contributed Indexing:
Keywords: anti-angiogenesis agents; overall survival; real life conditions; renal cell carcinoma; sequential treatments
Substance Nomenclature:
0 (Angiogenesis Inhibitors)
0 (Protein Kinase Inhibitors)
2S9ZZM9Q9V (Bevacizumab)
9HW64Q8G6G (Everolimus)
Entry Date(s):
Date Created: 20190719 Date Completed: 20200214 Latest Revision: 20200214
Update Code:
20240105
DOI:
10.1002/ijc.32578
PMID:
31318983
Czasopismo naukowe
The treatment landscape in metastatic renal cell carcinoma has changed fundamentally over the last decade by the development of antiangiogenic agents, mammalian target of rapamycin inhibitors and immunotherapy. Outside of the context of a clinical trial, the treatments are used sequentially. We describe results under real-life conditions of a sequential treatment strategy, before the era of immunotherapy. All patients were treated according to their prognostic score (either Memorial Sloan Kettering Cancer Center or International Metastatic Renal Cell Carcinoma Database Consortium) for advanced renal cell carcinoma. A treatment strategy involving 1 to 4 lines was determined including a rechallenge criterion for the repeat use of a treatment class. Three hundred forty-four patients were included over 3 years. Overall survival was 57 months in patients with good or intermediate prognosis and 19 months in patients with poor prognosis. In the former group, the proportions of patients treated with 2 to 4 treatment lines were 70%, 38% and 16%, respectively. The best objective response rates for lines 1 to 4 were 46%, 36%, 16% and 17%, respectively. Grade III/IV toxicity did not appear to be cumulative. The recommended strategy was followed in 68% of patients. A large proportion of patients with good or intermediate prognosis who progress after two lines of treatment still have a performance status good enough to receive a systemic treatment, which justifies such a strategy. Overall survival of patients with good and intermediate prognosis was long, suggesting a benefit from the applied approach. These results might be used as selection criterion for the treatment of patients in the era of immune checkpoint inhibitors.
(© 2019 UICC.)
Comment in: Ann Transl Med. 2019 Dec;7(Suppl 8):S272. (PMID: 32015991)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies